Please Wait
Applying Filters...
menu
    • menu
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Guizhou Utide Biotechnology Co., Ltd. - Specialized GMP manufacturing for next-generation GLP-1 peptide APIs.

    Virtual Booth

    Contact Supplier

    Menu

    BLU 667

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    CStone announces first patient dosed in China with BLU-667
    CStone announces first patient dosed in China with BLU-667

    12 Aug 2019

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/cstone-announces-first-patient-dosed-in-china-with-blu-667-for-the-global-phase-i-registrational-study-300900523.html

    PR NEWSWIRE
    12 Aug 2019
    Share Share
    Shrinking 60% of lung cancers, Blueprint's RET drug poised for 2020 filing
    Shrinking 60% of lung cancers, Blueprint's RET drug poised for 2020 filing

    04 Jun 2019

    // Amirah Al Idrus FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/asco-shrinking-60-lung-cancers-blueprint-s-ret-drug-poised-for-2020-filing

    Amirah Al Idrus FIERCE BIOTECH
    04 Jun 2019
    Share Share
    Bio Roundup: Amarin’s Stunner, Lung Cancer News, Data Dumps & More
    Bio Roundup: Amarin’s Stunner, Lung Cancer News, Data Dumps & More

    28 Sep 2018

    // Ben Fidler XCONOMY

    https://www.xconomy.com/national/2018/09/28/bio-roundup-amarins-stunner-lung-cancer-news-data-dumps-more/

    Ben Fidler XCONOMY
    28 Sep 2018
    Share Share
    Blueprint’s Tagrisso combination shows early promise in NSCLC
    Blueprint’s Tagrisso combination shows early promise in NSCLC

    26 Sep 2018

    // Amirah Al Idrus FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/blueprint-s-tagrisso-combo-shows-early-promise-nsclc

    Amirah Al Idrus FIERCE BIOTECH
    26 Sep 2018
    Share Share
    Blueprint Medicines Announces P-o-C Data of BLU-667 and Osimertinib in NSCLC
    Blueprint Medicines Announces P-o-C Data of BLU-667 and Osimertinib in NSCLC

    25 Sep 2018

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/blueprint-medicines-announces-proof-of-concept-data-showing-combination-of-blu-667-and-osimertinib-overcame-treatment-resistance-in-two-patients-with-egfr-mutant-non-small-cell-lung-cancer-and-an-acquired-ret-fusion-300718953.html

    PR NEWSWIRE
    25 Sep 2018
    Share Share
    Blueprint Medicines Announces Updated Data from Pha1 EXPLORER CTRLof Avapritinib
    Blueprint Medicines Announces Updated Data from Pha1 EXPLORER CTRLof Avapritinib

    15 Jun 2018

    // PRESS RELEASE

    http://ir.blueprintmedicines.com/phoenix.zhtml?c=253931&p=irol-newsArticle&ID=2354759

    PRESS RELEASE
    15 Jun 2018
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.